These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 10227000)

  • 21. [Treatment of ascites, hyponatremia and hepatorenal syndrome in liver cirrhosis].
    Ackermann D
    Ther Umsch; 2009 Nov; 66(11):747-51. PubMed ID: 19885792
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club.
    Arroyo V; Ginès P; Gerbes AL; Dudley FJ; Gentilini P; Laffi G; Reynolds TB; Ring-Larsen H; Schölmerich J
    Hepatology; 1996 Jan; 23(1):164-76. PubMed ID: 8550036
    [No Abstract]   [Full Text] [Related]  

  • 23. [Physiopathology of refractory ascites and the hepatorenal syndrome].
    Arroyo V
    Nefrologia; 2002; 22 Suppl 5():41-6. PubMed ID: 12107916
    [No Abstract]   [Full Text] [Related]  

  • 24. Hepatorenal syndrome.
    Biswas KD; Jain AK
    Trop Gastroenterol; 2002; 23(3):113-6. PubMed ID: 12693150
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of cirrhotic ascites.
    Bashyam M; Lepore M; Harbord M
    Br J Hosp Med (Lond); 2015 Feb; 76(2):C28-32. PubMed ID: 25671487
    [No Abstract]   [Full Text] [Related]  

  • 26. [Hepatorenal syndrome: diagnosis, treatment and prevention].
    Egerod Israelsen M; Gluud LL; Bendtsen F; Møller S; Krag AA
    Ugeskr Laeger; 2013 May; 175(22):1562-6. PubMed ID: 23721840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome.
    Arroyo V; Terra C; Ginès P
    J Hepatol; 2007 May; 46(5):935-46. PubMed ID: 17391801
    [No Abstract]   [Full Text] [Related]  

  • 28. Effects of plasma expansion with albumin and paracentesis on haemodynamics and kidney function in critically ill cirrhotic patients with tense ascites and hepatorenal syndrome: a prospective uncontrolled trial.
    Umgelter A; Reindl W; Wagner KS; Franzen M; Stock K; Schmid RM; Huber W
    Crit Care; 2008; 12(1):R4. PubMed ID: 18197961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Approach to the patient with zirrhotic ascites--no diagnosis without a tap].
    Umgelter A
    MMW Fortschr Med; 2010 Oct; 152(42):36-8. PubMed ID: 21140951
    [No Abstract]   [Full Text] [Related]  

  • 30. Pathophysiology, diagnosis and treatment of ascites in cirrhosis.
    Arroyo V
    Ann Hepatol; 2002; 1(2):72-9. PubMed ID: 15115971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transjugular intrahepatic portosystemic shunt in the management of ascites and hepatorenal syndrome.
    Senzolo M; Cholongitas E; Tibballs J; Burroughs A; Patch D
    Eur J Gastroenterol Hepatol; 2006 Nov; 18(11):1143-50. PubMed ID: 17033432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
    Testino G; Ferro C; Sumberaz A; Messa P; Morelli N; Guadagni B; Ardizzone G; Valente U
    Hepatogastroenterology; 2003; 50(54):1753-5. PubMed ID: 14696397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Therapy of complications of hepatic cirrhosis].
    Töx U; Goeser T
    Praxis (Bern 1994); 2005 May; 94(18):727-33. PubMed ID: 15938384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The therapy of the hepatorenal syndrome in liver cirrhosis].
    Biecker E; Brensing KA; Perz J; Woitas R; Sauerbruch T
    Dtsch Med Wochenschr; 1999 Sep; 124(36):1039-42. PubMed ID: 10506842
    [No Abstract]   [Full Text] [Related]  

  • 35. Update on peripheral arterial vasodilation, ascites and hepatorenal syndrome in cirrhosis.
    Knotek M; Rogachev B; Schrier RW
    Can J Gastroenterol; 2000 Nov; 14 Suppl D():112D-121D. PubMed ID: 11110623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatorenal syndrome.
    Bataller R; Ginès P; Arroyo V; Rodés J
    Clin Liver Dis; 2000 May; 4(2):487-507. PubMed ID: 11232202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
    Wong F; Pantea L; Sniderman K
    Hepatology; 2004 Jul; 40(1):55-64. PubMed ID: 15239086
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fluid retention in cirrhosis: pathophysiology and management.
    Kashani A; Landaverde C; Medici V; Rossaro L
    QJM; 2008 Feb; 101(2):71-85. PubMed ID: 18184668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of ascites in patients with cirrhosis of the liver.
    Arroyo V; Ginés P; Rodés J
    Intensive Care Med; 1987; 13(3):154-61. PubMed ID: 3584645
    [No Abstract]   [Full Text] [Related]  

  • 40. Diagnosis and treatment of ascites.
    Tsochatzis EA; Gerbes AL
    J Hepatol; 2017 Jul; 67(1):184-185. PubMed ID: 28119010
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.